767 related articles for article (PubMed ID: 19965662)
41. Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Izutsu K; Yamamoto K; Kato K; Ishikawa T; Fukuhara N; Terui Y; Choi I; Humphrey K; Kim SY; Okubo S; Ogawa N; Nishimura Y; Salem AH; Maruyama D
Int J Hematol; 2021 Mar; 113(3):370-380. PubMed ID: 33094474
[TBL] [Abstract][Full Text] [Related]
42. Membrane-associated signaling in human B-lymphoma lines.
Tauzin S; Ding H; Burdevet D; Borisch B; Hoessli DC
Exp Cell Res; 2011 Jan; 317(2):151-62. PubMed ID: 20875408
[TBL] [Abstract][Full Text] [Related]
43. An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma.
Andorsky DJ; Kolibaba KS; Assouline S; Forero-Torres A; Jones V; Klein LM; Patel-Donnelly D; Smith M; Ye W; Shi W; Yasenchak CA; Sharman JP
Br J Haematol; 2019 Jan; 184(2):215-222. PubMed ID: 30183069
[TBL] [Abstract][Full Text] [Related]
44. DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma.
Flinn IW; Miller CB; Ardeshna KM; Tetreault S; Assouline SE; Mayer J; Merli M; Lunin SD; Pettitt AR; Nagy Z; Tournilhac O; Abou-Nassar KE; Crump M; Jacobsen ED; de Vos S; Kelly VM; Shi W; Steelman L; Le N; Weaver DT; Lustgarten S; Wagner-Johnston ND; Zinzani PL
J Clin Oncol; 2019 Apr; 37(11):912-922. PubMed ID: 30742566
[TBL] [Abstract][Full Text] [Related]
45. Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial.
Nastoupil LJ; Lunning MA; Vose JM; Schreeder MT; Siddiqi T; Flowers CR; Cohen JB; Burger JA; Wierda WG; O'Brien S; Sportelli P; Miskin HP; Purdom MA; Weiss MS; Fowler NH
Lancet Haematol; 2019 Feb; 6(2):e100-e109. PubMed ID: 30709431
[TBL] [Abstract][Full Text] [Related]
46. Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
Byrd JC; Harrington B; O'Brien S; Jones JA; Schuh A; Devereux S; Chaves J; Wierda WG; Awan FT; Brown JR; Hillmen P; Stephens DM; Ghia P; Barrientos JC; Pagel JM; Woyach J; Johnson D; Huang J; Wang X; Kaptein A; Lannutti BJ; Covey T; Fardis M; McGreivy J; Hamdy A; Rothbaum W; Izumi R; Diacovo TG; Johnson AJ; Furman RR
N Engl J Med; 2016 Jan; 374(4):323-32. PubMed ID: 26641137
[TBL] [Abstract][Full Text] [Related]
47. Spleen tyrosine kinase (Syk) inhibitor fostamatinib limits tissue damage and fibrosis in a bleomycin-induced scleroderma mouse model.
Pamuk ON; Can G; Ayvaz S; Karaca T; Pamuk GE; Demirtas S; Tsokos GC
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S15-22. PubMed ID: 26148346
[TBL] [Abstract][Full Text] [Related]
48. Healing the Syk through kinase inhibitors.
Rivera J; Colbert RA
N Engl J Med; 2010 Sep; 363(14):1362-4. PubMed ID: 20879886
[No Abstract] [Full Text] [Related]
49. A Phase I Trial of SYK Inhibition with Fostamatinib in the Prevention and Treatment of Chronic Graft-Versus-Host Disease.
Lin C; DiCioccio RA; Haykal T; McManigle WC; Li Z; Anand SM; Poe JC; Bracken SJ; Jia W; Alyea EP; Cardones AR; Choi T; Gasparetto C; Grunwald MR; Hennig T; Kang Y; Long GD; Lopez R; Martin M; Minor KK; Quinones VLP; Sung AD; Wiggins K; Chao NJ; Horwitz ME; Rizzieri DA; Sarantopoulos S
Transplant Cell Ther; 2023 Mar; 29(3):179.e1-179.e10. PubMed ID: 36577483
[TBL] [Abstract][Full Text] [Related]
50. Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib.
Sun C; Nierman P; Kendall EK; Cheung J; Gulrajani M; Herman SEM; Pleyer C; Ahn IE; Stetler-Stevenson M; Yuan CM; Maric I; Gaglione EM; Harris HM; Pittaluga S; Wang MH; Patel P; Farooqui MZH; Izumi R; Hamdy A; Covey T; Wiestner A
Blood; 2020 Jul; 136(1):93-105. PubMed ID: 32202637
[TBL] [Abstract][Full Text] [Related]
51. From CLL to Multiple Myeloma - Spleen Tyrosine Kinase (SYK) influences multiple myeloma cell survival and migration.
Lorenz J; Waldschmidt J; Wider D; Follo M; Ihorst G; Chatterjee M; May AM; Duyster J; Rosenwald A; Wäsch R; Zirlik K; Engelhardt M
Br J Haematol; 2016 Sep; 174(6):985-9. PubMed ID: 26491948
[No Abstract] [Full Text] [Related]
52. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study.
Xu W; Yang S; Zhou K; Pan L; Li Z; Zhou J; Gao S; Zhou D; Hu J; Feng R; Huang H; Ji M; Guo H; Huang J; Novotny W; Feng S; Li J
J Hematol Oncol; 2020 May; 13(1):48. PubMed ID: 32393328
[TBL] [Abstract][Full Text] [Related]
53. Pharmacokinetics of fostamatinib, a spleen tyrosine kinase (SYK) inhibitor, in healthy human subjects following single and multiple oral dosing in three phase I studies.
Baluom M; Grossbard EB; Mant T; Lau DT
Br J Clin Pharmacol; 2013 Jul; 76(1):78-88. PubMed ID: 23190017
[TBL] [Abstract][Full Text] [Related]
54. Syk-induced phosphatidylinositol-3-kinase activation in Epstein-Barr virus posttransplant lymphoproliferative disorder.
Hatton O; Lambert SL; Phillips LK; Vaysberg M; Natkunam Y; Esquivel CO; Krams SM; Martinez OM
Am J Transplant; 2013 Apr; 13(4):883-890. PubMed ID: 23398911
[TBL] [Abstract][Full Text] [Related]
55. Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies.
Mahadevan D; Chiorean EG; Harris WB; Von Hoff DD; Stejskal-Barnett A; Qi W; Anthony SP; Younger AE; Rensvold DM; Cordova F; Shelton CF; Becker MD; Garlich JR; Durden DL; Ramanathan RK
Eur J Cancer; 2012 Dec; 48(18):3319-27. PubMed ID: 22921184
[TBL] [Abstract][Full Text] [Related]
56. Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia.
Herman SE; Barr PM; McAuley EM; Liu D; Wiestner A; Friedberg JW
Leukemia; 2013 Aug; 27(8):1769-73. PubMed ID: 23385377
[No Abstract] [Full Text] [Related]
57. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Munir T; Brown JR; O'Brien S; Barrientos JC; Barr PM; Reddy NM; Coutre S; Tam CS; Mulligan SP; Jaeger U; Kipps TJ; Moreno C; Montillo M; Burger JA; Byrd JC; Hillmen P; Dai S; Szoke A; Dean JP; Woyach JA
Am J Hematol; 2019 Dec; 94(12):1353-1363. PubMed ID: 31512258
[TBL] [Abstract][Full Text] [Related]
58. Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk.
Podolanczuk A; Lazarus AH; Crow AR; Grossbard E; Bussel JB
Blood; 2009 Apr; 113(14):3154-60. PubMed ID: 19096013
[TBL] [Abstract][Full Text] [Related]
59. Activities of SYK and PLCgamma2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinib.
Song Z; Lu P; Furman RR; Leonard JP; Martin P; Tyrell L; Lee FY; Knowles DM; Coleman M; Wang YL
Clin Cancer Res; 2010 Jan; 16(2):587-99. PubMed ID: 20068106
[TBL] [Abstract][Full Text] [Related]
60. B-cell antigen receptor signaling in chronic lymphocytic leukemia: therapeutic targets and translational opportunities.
Hill RJ; Lou Y; Tan SL
Int Rev Immunol; 2013 Aug; 32(4):377-96. PubMed ID: 23886341
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]